

Amphetamine increases blood pressure and heart rate but has no effect on motor recovery or cerebral haemodynamics in ischaemic stroke: a randomised controlled trial (ISRCTN 36285333)

Nikola Sprigg,¹ MRCP; Mark R Willmot,¹ MRCP; Laura J Gray,¹ MSc; Alan Sunderland,² PhD; Valerie Pomeroy,³ PhD; Marion Walker,⁴ PhD; Philip M W Bath,¹ MD FRCP

Stroke Trials Unit,¹ School of Psychology,² and Department of Ageing and Rehabilitation,⁴ University of Nottingham, UK; Centre for Rehabilitation and Ageing³, St. George's Hospital Medical School, University of London, UK

Corresponding author:

Professor Philip Bath
Division of Stroke Medicine
University of Nottingham
Nottingham City campus
Nottingham
NG5 1PB

Tel: 0115 823 1765

Fax: 0115 823 1767

Email: philip.bath@nottingham.ac.uk

Running Title:

Amphetamine increases blood pressure not recovery

List of Tables and Figures:

Table 1 Baseline characteristics of patients

Table 2 Outcome by treatment group

Table 3 Haemodynamic measures by treatment group

Table 4 Number of patients suffering serious adverse events (SAE) by treatment group

Figure 1 Trial Design

Figure 2a Updated forest plot (meta-analysis) of effect of amphetamine on motor improvement

Figure 2b Updated forest plot (meta-analysis) of effect of amphetamine on systolic blood pressure

Keywords: ischaemic stroke, stroke recovery, amphetamine

Word Count:

ABSTRACT

Background: Amphetamine enhances recovery after experimental ischaemia and has shown promise in small clinical trials when combined with motor or sensory stimulation. Amphetamine, a sympathomimetic, might have haemodynamic effects in stroke patients, although limited data have been published.

Methods: Subjects were recruited 3-30 days post ischaemic stroke into a phase II randomised (1:1), double blind, placebo-controlled trial. Subjects received dexamphetamine (5mg initially, then 10mg for 10 subsequent doses with 3 or 4 day separations) or placebo in addition to inpatient physiotherapy. Recovery was assessed by motor scales (Fugl-Meyer, FM), and functional scales (Barthel index, BI and modified Rankin score, mRS). Peripheral blood pressure (BP), central haemodynamics and middle cerebral artery blood flow velocity were assessed before, and 90 minutes after, the first 2 doses.

Results: 33 subjects were recruited, age 33-88 (mean 71) years, males 52%, 4-30 (median 15) days post stroke to inclusion. 16 patients were randomised to placebo and 17 amphetamine. Amphetamine did not improve motor function at 90 days; mean (standard deviation) FM 37.6 (27.6) vs. control 35.2 (27.8) ($p=0.81$). Functional outcome (BI, mRS) did not differ between treatment groups. Peripheral and central systolic BP, and heart rate, were 11.2 mmHg ($p=0.03$), 9.5 mmHg ($p=0.04$) and 7 beats/minute ($p=0.02$) higher respectively with amphetamine, compared with control. A non-significant reduction in myocardial perfusion (Buckberg Index) was seen with amphetamine. Other cardiac and cerebral haemodynamics were unaffected.

Conclusion: Amphetamine did not improve motor impairment or function after ischaemic stroke but did significantly increase BP and heart rate without altering cerebral haemodynamics.

INTRODUCTION

Modern concepts in stroke recovery now include the brain's capacity to undergo dynamic plastic change.¹ This plasticity is exploited by rehabilitation which is effective at improving outcome, and it might be possible to enhance this recovery further using pharmacological means,² an approach that has been referred to as 'pharmacological rehabilitation'.^{3,4}

In experimental models cerebral ischaemia results in a catecholamine deficit, whilst drugs that negatively regulate central neurotransmitters, such as haloperidol, (a dopamine receptor antagonist), have detrimental effects on outcome in both experimental and clinical stroke.^{5,6} It has been hypothesised that increasing catecholamines could facilitate recovery following stroke, and that centrally acting neurotransmitters might modulate plasticity.^{7,8}

Amphetamine, a sympathomimetic drug, has been shown to accelerate the recovery of motor function in experimental models of stroke when given in conjunction with task specific practice.^{5,9,10} However, timing and dose of administration appears important; high doses and early administration being associated with a poor outcome,^{5,11} whilst pre-treatment with amphetamine led to increased ischemic insult.¹² The evidence in normal subjects¹³⁻¹⁵ and in clinical stroke is less clear,¹⁶⁻²⁷ numerous small trials, utilizing varying dosage and timing of treatment, showing conflicting results, overall demonstrating no evidence of benefit on motor recovery. Whilst treatment appears feasible and well tolerated, a trend to increased death in the treatment group exists on meta-analysis.²⁸ As such, there is currently no evidence to support the routine use of amphetamine.

Despite well documented systemic effects of amphetamine,²⁹ in particular its effect of raising blood pressure (BP) and heart rate (HR), limited data exist regarding the effect of amphetamine on peripheral haemodynamics in patient with recent ischaemic stroke. One trial found that amphetamine increased BP and HR in stroke,³⁰ important as hypertension is a major risk factor for further stroke,³¹ and for a poor outcome.³² Furthermore, no data exist on the effect of amphetamine on central or cerebral haemodynamic in this population, despite recent evidence that these parameters can be related to outcome in acute stroke.^{33,34}

We performed a phase II trial assessing the effect of amphetamine on motor function, and cerebral and cardiac haemodynamics. We hypothesised that amphetamine would improve recovery from stroke when given with physiotherapy, and sympathomimetic actions would increase blood pressure and heart rate, and alter cardiac haemodynamics and cerebral blood flow velocity.

METHODS

Design

We performed a prospective, single-centre, double-blind, randomised placebo-controlled phase II trial of amphetamine in patients with recent ischaemic stroke. A sample size of 42 was required based on an unpublished meta-analysis of 4 small trials^{16, 17, 19, 25} which showed a beneficial effect of amphetamine on motor impairment assessed as the Fugl-Meyer motor scale: randomisation ratio of 1:1, mean treatment difference 16.2, with standard deviation 18.8, alpha = 0.05 and 80% power. The study was approved by the Nottingham Local Research Committee (October 2001), had a Medicines and Healthcare products Regulatory Agency Clinical Trial Authorisation (August 2001), and International trial number (ISRCTN 36285333), and was performed according to the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practice guidelines.

Subjects

Previously independent (modified Rankin score, mRS <3) adult patients with recent ischaemic stroke (3-30 days post ictus) and motor weakness (arm and leg components of Scandinavian Stroke Scale, SSS < 6) were identified and enrolled from Nottingham City Hospital (NCH). Patients were recruited as early as possible after 3 days once they had become clinically stable. The principal exclusion criteria were contra-indications to amphetamine, including intracerebral haemorrhage, ischaemic heart disease, uncontrolled hypertension (>160/100mmHg), thyrotoxicosis and history of seizures; patients with dementia, coma, or pregnancy were also excluded. Full written informed consent was obtained from patients prior to randomisation, or assent taken from a relative/carer if the patient was incompetent, confused or dysphasic.

Intervention

Patients were randomised to receive either amphetamine or placebo using computerised minimisation on age, sex, baseline severity (SSS), and baseline Motricity Index upper extremity score. Dexamphetamine sulphate (initial 5mg dose followed by 10mg thereafter) or placebo was administered orally twice a week with alternating 3 or 4 day separations.^{17, 23, 24, 26, 35, 36} The dose of 10mg is unlikely to cause dependency or extreme vascular instability. There were a total of 11 doses covering a treatment period of 35 days. Treatment was given 1-2 hours before scheduled physiotherapy.

Outcome measures

The primary outcome was motor impairment as assessed by Fugl-Meyer (upper extremity) motor scale (FM) at day 90. Secondary outcomes included Motricity Index (upper limb) (MI), severity (SSS), Barthel Index (BI), modified Rankin Scale (mRS), extended activity of daily living (EADL), language skills (Sheffield screening test), cognition (mini-mental state examination), mood (Zung depression score), and quality of life (health state test); these were assessed at the end of treatment (day 35) and day 90. Discharge disposition and length of hospital stay were also recorded. Safety was assessed as mortality, serious adverse events (SAE), stroke recurrence (ischaemic or haemorrhagic), acute coronary syndrome (myocardial infarction, unstable angina), and symptomatic cardiac dysrhythmia during the study period.

Haemodynamic measures

Cerebral and cardiac measurements were made immediately before and 90 minutes after both the first (dexamphetamine 5mg) and second treatment (dexamphetamine 10mg) doses. Peripheral systolic and diastolic blood pressure (SBP, DBP) and heart rate (HR) were measured with a validated digital readout oscillometric device (Omron HEM-705CP, Illinois, US). Pulse pressure (PP = SBP - DBP) and rate pressure product (RPP = HR x SBP) were calculated from measured parameters.³⁷ Central BP, mean arterial pressure (MAP), compliance (augmentation index, AI) and myocardial perfusion (Buckberg index, BUI³⁸) were assessed by applanation tonometry pulse wave analysis (SphygmoCor Px, Australia) at the radial artery. Cardiac output

and peripheral vascular resistance were measured by Portapres (NO-TPD Biomedical Instrumentation, Amsterdam, Netherlands).

The middle cerebral artery (MCA) was insonated bilaterally by transcranial Doppler (Nicolet EME Companion, Kleimoftheim, Germany)³⁹ and systolic flow velocity (SFV), diastolic flow velocity (DFV), mean flow velocity (MFV) and pulsatility index (PI) recorded. Estimated cerebral perfusion pressure (CPP) was calculated using a mean of contra-lateral and ipsilateral cerebral blood flow velocity as follows:^{40, 41} $CPP = (MFV / (MFV - DFV)) \times (MAP - DBP)$.

All clinical measurements were performed blinded to treatment assignment, and outcome measures were performed blinded to haemodynamic measures and treatment. Measurements were not adjusted for concurrent antihypertensive therapy (as with previous studies) since this was very variable depending, in part, on the supervising consultant's medical practice.

Statistical methods

Data are presented as mean (standard deviation, SD), median (interquartile range, IQR) or number (%), and were analysed using Fisher's exact test, student t test, Mann Whitney U test, or comparison by ANCOVA with adjustment for baseline values, as appropriate. All analyses were performed using SPSS (Apple Mac, version 11; SPSS Inc, Chicago, USA). Analysis was by intention-to-treat; significance was taken at $p < 0.05$.

RESULTS

Subjects

Thirty three patients (of an intended 42) were enrolled between September 2001 and December 2005 (figure 1); enrolment was concluded early due to the low recruitment rate. Patients were enrolled 15 days (range 4 - 30 days) after stroke. Patients assigned to amphetamine were more likely to be male than in the placebo group otherwise both groups were matched for age, baseline blood pressure and stroke severity (table 1).

Recovery

There was no difference between treatment groups in Fugl-Meyer scores (primary outcome) at day 90 (table 2). Similarly, there was no difference between groups in the secondary outcome measures of impairment (MI, SSS) or function (BI, mRS and EADL) at day 35 or day 90. Length of stay and discharge disposition did not differ between treatment groups (table 2). No differences were observed between the treatment groups in terms of language skills (Sheffield screening test), cognition (mini-mental state examination), mood (Zung depression score) or quality of life (health state test) (data not shown).

Haemodynamic measures

Both groups were well matched for baseline blood pressure (table 1), although patients assigned to placebo had a higher heart rate, whilst patients in the amphetamine group had higher cerebral blood flow velocities. Peripheral and central BP were 11.2/5.8 mmHg and 9.5/6.6 mmHg higher respectively after amphetamine than placebo (table 3). Pulse pressure was unaffected by amphetamine. Heart rate was significantly increased by 7-9 beats/minute after amphetamine (table 3). Rate pressure product was increased after amphetamine, with a trend to a reduction in myocardial perfusion (Buckberg Index) present after the second dose of amphetamine (table 3). Other cardiac haemodynamics, including vessel compliance, cardiac output and total peripheral resistance were unaffected by amphetamine. Similarly, amphetamine did not significantly alter middle cerebral artery blood flow velocity or estimates of cerebral perfusion pressure (table 3).

Safety

No patients died during the course of the study, 1 patient each had a recurrent ischaemic stroke (placebo group) and transient ischaemic attack (placebo group) (table 4). There were no episodes of acute coronary syndrome, or symptomatic dysrhythmia or epilepsy. Serious adverse event rates did not differ between treatment groups (4 vs. 3, $p=0.69$) (table 4).

DISCUSSION

This phase II trial set out to assess the effect of amphetamine on functional outcome and haemodynamic parameters in patients with recent ischaemic stroke. The primary hypothesis that amphetamine would reduce motor impairment was not supported. Additionally, there were no effects on other measures of impairment, disability, mood and quality of life. Early studies of amphetamine after stroke suggested motor impairment might be reduced,^{16, 17, 19, 25} data we used to power the present trial. However, more recent studies have not supported this finding. Taking all the studies together (including that reported here), a meta-analysis reveals no evidence of efficacy, standardised mean difference (SMD) 0.12 (95% CI, -0.25 to 0.50) (figure 2a).

Amphetamine is known to have powerful effects on blood pressure and heart rate in normal subjects; indeed, a sympathetic surge resulting in hypertension is well recognised as a cause of stroke when recreational doses of the drug are taken.⁴² Unsurprisingly, amphetamine also increased peripheral blood pressure and heart rate in the present study, as has been found in earlier trials in patients with recent stroke.^{22, 26} Meta-analysis of these data show that amphetamine increases systolic BP (weighted mean difference) by 9.3 mmHg (95% CI, 3.3 to 15.3) (figure 2b) and HR by 7.6 beats per minute (95% CI, 1.9 to 13.4).

Other haemodynamic parameters are associated with stroke in epidemiological studies⁴³ and amphetamine appears to alter some of these. Central BP (rather than peripheral brachial BP) is more relevant to the cerebral circulation and amphetamine increased this. Rate-pressure product (the mathematical product of heart rate and systolic BP,⁴⁴ an index of myocardial work and associated with a poor outcome after stroke³⁴) was similarly increased with amphetamine. In parallel, the Buckberg Index (an estimate of myocardial perfusion) was decreased non significantly after amphetamine. Buckberg Index is affected by heart rate, with tachycardia resulting in shortened diastole and the potential for reduced coronary artery filling. Hence, the positive chronotropic effect of amphetamine may explain, in part, a tendency for myocardial perfusion to decrease.

Elevation of systemic blood pressure, in the presence of dysfunctional cerebral autoregulation (as occurs in acute ischaemic stroke), might lead to an increase in cerebral blood flow and, potentially, enhance recovery after stroke.³³ However, despite increasing blood pressure, no changes in middle cerebral artery blood flow velocity or estimated cerebral perfusion pressure were observed with amphetamine. Changes in cerebral blood flow with amphetamine have been demonstrated previously,⁴⁵ although these appeared to be region-specific and, therefore, are probably not detectable using global measures of flow and perfusion (as utilised here).

The lack of effect of amphetamine on recovery may be due to a number of reasons. First, enrolment in this study was terminated early due to a low recruitment rate (a problem seen in other trials with limiting inclusion criteria^{24, 46}) so the intended sample size was not achieved thereby leading to a potential type II error when viewed in the context of the pre-trial sample size calculation. This problem was compounded by the heterogeneous nature of recruited patients with widely varying impairment at baseline. Unfortunately, the limited sample size prevents stratification of data by prognostic baseline factors such as stroke syndrome, severity or time to recruitment. Furthermore, to date, no clinical study testing amphetamine in stroke has taken into account ischaemic lesion size or location.²⁷ Additionally, contemporary care of ischaemic stroke has evolved over the recruitment period of this study, which may also have introduced further heterogeneity. However, the management of blood pressure in acute stroke has not altered during this time. Second, no single outcome measure has been used in the existing amphetamine trials, so the potential for meta-analysis is limited and, again, a type II error may be present. In keeping with this, many of the outcome measures utilised demonstrate ceiling effects, although some studies have excluded patients with mild weakness in an attempt

to overcome this.^{17, 21, 24, 27} Third, suboptimal dose regimes might have been tested; the regime utilised here (and pioneered by others^{17, 23, 24, 26, 35, 36}) was driven by concern for potential adverse effects. It is possible that higher and more frequent doses are required, as tested in experimental models.^{5, 9, 47, 48} Fourth, treatment was started between 4 and 30 days after stroke onset. Similar studies have failed to address the issue of most favourable time to recruitment and the optimal therapeutic window remains to be elucidated. Finally, perhaps amphetamine has no overall effect on recovery, reflecting a balance between potential benefit and harm. Amphetamine might enhance plasticity, thus reducing impairment, whilst also increasing risk factors for a poor outcome. For example, elevating BP and heart rate will increase myocardial work load (rate-pressure product), as seen here, whilst tachycardia will reduce myocardial perfusion (Buckberg Index), a pattern which is likely to promote cardiac events, particularly since many patients with stroke have existing heart disease (whether clinical or occult). Although experimental data supporting the use of amphetamine, whether in animals or normal volunteers, has involved subjects with normal coronary vasculature,^{14, 15, 49} a trend to increased death in stroke patients has been noted previously²⁸ (although not seen in the present study) which supports this hypothesis.

We did not show any benefit of amphetamine therapy on recovery after ischaemic stroke although a moderate treatment effect, whether beneficial or hazardous, cannot be excluded. Amphetamine increased peripheral and central BP, heart rate, myocardial work rate and tended to reduce myocardial perfusion. In contrast, it had no effect on other central haemodynamic measures or middle cerebral artery blood flow velocity. Combining these data with those of previous studies, we find no evidence that amphetamine improves motor recovery, perhaps because it induces potentially hazardous effect on systemic haemodynamic parameters. Any future trials of amphetamine should further study its effects on haemodynamic measures.

ACKNOWLEDGMENTS CONTRIBUTIONS AND FUNDING

We thank therapists Helen Hill, Christine Walker, Louise Connell and Jeremy Newton for performing outcome assessments. PB, MW, VP and AS conceived, designed and supervised the study; MRW and NS recruited patients and performed systemic and cerebral haemodynamic studies; NS and LG performed the statistical analyses; NS and PB wrote the first draft of the manuscript, all the other authors commented on and approved the final draft; PB is the study guarantor. Support was received from BUPA Foundation (NS, LG) and The Hypertension Trust (MRW). PB is Stroke Association Professor of Stroke Medicine.

CONFLICT OF INTEREST STATEMENT

No company manufacturing amphetamine or developing it for stroke was involved in the conception, execution, analysis, or interpretation of the study, and none has commented on the manuscript.

References

1. Johansson B. Brain Plasticity and stroke rehabilitation; the Willis Lecture. *Stroke*. 2000;31:223
2. Meairs S, Wahlgren N, Dirnagl U, Lindvall O, Rothwell P, Baron J-C, et al. Stroke Research Priorities for the Next Decade -- A Representative View of the European Scientific Community. *CerebrovascDis*. 2006;22:75-82
3. Sprigg N, Bath PMW. Pharmacological enhancement of recovery from stroke. *Current Medical Literature: Stroke Review*. 2005;8:33-39
4. Philips JP, Devier DJ, Feeney DM. Rehabilitation Pharmacology: Bridging Laboratory Work to Clinical Application. *Journal of Head Trauma Rehabilitation*. 2003;18:342-356
5. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. *Science*. 1982;217:855-857
6. Goldstein L. Potential effects of common drugs on stroke recovery. *Arch Neurol*. 1999;55:454-456
7. Gladstone DG, Black SE, 1772. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? *CanJNeuroSci*. 2000;27:97-105
8. Ziemann U, Meintzschel F, Korchounov A, Ilic T. Pharmacological Modulation of Plasticity in the Human Motor Cortex. *Neurorehabilitation and Neural Repair*. 2006;20:243 - 251
9. Hurwitz BE, Dietrich WD, McCabe PM, Alonso O, Watson BD, Ginsberg MD, et al. Amphetamine promotes recovery from sensory-motor integration deficit after thrombotic infarction of the primary somatosensory rat cortex. *Stroke*. 1991;22:648-654
10. Barbay S, Zoubina EV, Dancause N, Frost SB, Eisner-Janowicz I, Stowe AM, et al. A single injection of D-amphetamine facilitates improvements in motor training following a focal cortical infarct in squirrel monkeys. *Neurorehabil Neural Repair*. 2006;20:455-458
11. Brown AW, Bjelke B, Fuxe K. Motor response to amphetamine treatment, task-specific training, and limited motor experience in a postacute animal stroke model. *Experimental Neurology*. 2004;190:102-108
12. Wang Y, Hayashi T, Chang C-F, Chiang Y-H, Tsao L-I, Su T-P, et al. Methamphetamine Potentiates Ischemia/Reperfusion Insults after Transient Middle Cerebral Artery Ligation. *Stroke*. 2001;32:775-782
13. Knecht S, Imai T, Kamping S, Breitenstein C, Henningsen H, Lutkenhoner B, et al. D-amphetamine does not improve outcome of somatosensory training. *Neurology*. 2001;57:2248-2252
14. Nitsche M, Grundey J, Liebetanz D, Lang N, Tergau F, Paulus W. Catecholaminergic Consolidation of Motor Cortex Neuroplasticity in Humans. *Cerebral Cortex*. 2004;14:1240-1245
15. Meintzschel F, Ziemann U. Modifications of Practice-dependent Plasticity in Human Motor Cortex by Neuromodulators. *Cerebral Cortex*. 2006;16:1106 - 1115
16. Crisostomo EA, Duncan PW, Propst M, Dawson DV, Davis JN. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. *AnnNeurol*. 1988;23:94-97
17. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R, 1339. Amphetamine paired with physical therapy accelerates motor recovery after stroke. *Stroke*. 1995;26:2254-2259
18. Reding MJ, Solomon B, Borucki S, 1365. Effect of dextroamphetamine on motor recovery after stroke. *Neurology*. 1995;45 Suppl 4:a222
19. Mazagri R, Shuaib A, McPherson M, Deighton M. Amphetamine failed to improve motor function in acute stroke (Abstract). *Can.J.Neurol.Sci*. 1995;22(2)(Suppl 1):S25
20. Vachalathiti R, Asavavalloh C, Nilanont Y, Pongvarin N. Comparison of physical therapy and physical therapy with amphetamines in sensorimotor recovery of acute stroke patients: randomised control. *J Neurol Sci*. 2001;187:S253 (Abst. P0724)
21. Treig T, Werner C, Sachse M, Hesse S. No benefit from D-amphetamine when added to physiotherapy after stroke: a randomised placebo-controlled study. *Clinical Rehabilitation*. 2003;17:590-599
22. Martinsson L, Wahlgrew NG, Hardemark H. Safety of dexamphetamine in acute ischaemic stroke-randomized double-blind controlled dose escalation trial. *Stroke*. 2003;34:475-481
23. Sonde L, Nordstrom M, Nilsson CG, Lokk J. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke. *Cerebrovasc Dis*. 2001;12:253-257
24. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines WR, Graham SJ, et al. Physiotherapy coupled with Dextroamphetamine for rehabilitation after hemiparetic stroke. *Stroke*. 2006;37:179-185

25. Grade C, Redford B, Chrostowski J. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. *ArchPhysMedRehabil.* 1998;79:1047-1050
26. Platz T, Kim IH, Engel U, Pinkowski C, Eickhof C, Kutzner M. Amphetamine fails to facilitate motor performance and to enhance motor recovery among stroke patients with mild arm paresis: Interim analysis and termination of a double blind, randomised, placebo-controlled trial. *Restorative Neurology and Neuroscience.* 2005;23:271-280
27. Sonde L, Lökk J. Effects of amphetamine and/or l-dopa and physiotherapy after stroke - a blinded randomized study. *Acta Neurol Scand.* 2007;115:55-59
28. Martinsson L, Wahlgren NG, Hardemark H. Amphetamines for improving recovery after stroke (Cochrane Review). *The Cochrane Library.* 2003
29. British National Formulary. <http://bnf.org/bnf/index.htm.2006>
30. Martinsson L, Wahlgren NG. Safety of dexamphetamine in acute ischaemic stroke-randomized double-blind controlled dose escalation trial. *Stroke.* 2003;34:475-481
31. Prospective Studies Collaboration. Age specific relevance of usual blood pressure to vascular mortality: a meta analysis of individual data for one million adults in 61 prospective studies. *Lancet.* 2002;360:1903-1913
32. Leonardi-Bee J, Bath PM, Bousser MG, Davalos A, Diener H-C, Guiraud-Chaumeil B, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. *Stroke.* 2005;36:162-168
33. Carey LM, Abbott DF, Egan GF, Bernhardt J, Donnan GA. Motor impairment and recovery in the upper limb after stroke: Behavioural and Neuroanatomical correlates. *Stroke.* 2005;36:625-629
34. Sprigg N, Gray LJ, Bath PMW. Relationship between functional outcome and baseline blood pressure, pulse pressure and heart rate in acute ischaemic stroke: data from the TAIST trial. *Journal of Hypertension.* 2006;24:1413-1417
35. Walker-Batson Dea. A double-blind placebo-controlled study of the use of amphetamine in the treatment of aphasia. *Stroke.* 2001;32:2093-2098
36. Treig T, Werner C, Sachse. No benefit from D-amphetamine when added to physiotherapy after stroke: a randomised placebo-controlled study. *Clinical Rehabilitation.* 2003;17:590-599
37. Sprigg N, Gray LJ, Bath PMW, Sorensen P, Lindenstrom E, Boysen G, et al. Relationship between functional outcome and baseline blood pressure, pulse pressure and heart rate in acute ischaemic stroke: data from the TAIST trial. *Journal of Hypertension.* 2006;24:1413-1417
38. Buckberg GD. Subendocardial ischaemia after cardiopulmonary bypass. *Journal of Thorac Cardiovasc Surg.* 1972;64:669-684
39. Hennerici M, Rautenberg W, Sitzer G, Schwartz A. Transcranial doppler for the assessment of intracranial arterial flow velocity - Part 1. *Surgical Neurology.* 1987;27:439-448
40. Hancock S, Eastwood J, Mahajan R. Effects of inhaled nitrous oxide 50% on estimated cerebral perfusion pressure and zero flow pressure in healthy volunteers. *Anaesthesia.* 2005;60:129-132
41. Athanassiou L, Hancock S, Mahajan R. Doppler estimation of zero flow pressure during changes in downstream pressure in a bench model of a circulation using pulsatile flow. *Anaesthesia.* 2005;60:133-138
42. McEvoy AW, Kitchen ND, Thomas DGT. Intracerebral haemorrhage in young adults: the emerging importance of drug misuse. *British Medical Journal.* 2000;320:1322-1324
43. O'Rourke MF, Adji A. An updated clinical primer on large artery mechanics: implications of pulse waveform analysis and arterial tonometry. *Current Opinion in Cardiology.* 2005;20:275-281
44. Robinson BF. Relation of heart rate and systolic blood pressure to the onset of pain in angina pectoris. *Circulation.* 1967;35:1073-1083
45. Devous MD, Madhukar H, Trivedi MH, Rush AJ. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. *The Journal of Nuclear Medicine.* 2001;42:535-542
46. LaRue LJ, Alter M, Traaven ND, Sterman AB, Sobel E, Kleiner J. Acute stroke therapy trials: problems in patient accrual. *Stroke.* 1988;19:950-954
47. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. *Stroke.* 1998;29:2381-2393; discussion 2393-2385

48. Hovda DA, Fenney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. *Brain Res.* 1984;298:358-361
49. Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, et al. Modulation of Use-Dependent Plasticity by D-Amphetamine. *Annals of Neurology.* 2002;51:59-68
50. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. *Lancet.* 1991;337:1521-1526
51. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. *Stroke.* 1993;24:35-41

TABLE 1

Baseline characteristics of patients. Number (%), or mean (standard deviation)

Characteristic	Placebo (n = 16)	D-amphetamine (n = 17)
Age (years)*	73 (11)	69 (12)
Male (%)*	4 (25)	11 (65)
Time to treatment (days)	15 (7)	15 (8)
Clinical stroke syndrome (%) ⁵⁰		
Lacunar	6 (38)	8 (47)
Partial anterior circulation	5 (31)	4 (24)
Total anterior circulation	5 (31)	5 (29)
TOAST aetiological group (%) ⁵¹		
Small vessel disease	3 (19)	6 (35)
Large artery disease	2 (13)	2 (12)
Cardio-embolic stroke	2 (13)	4 (24)
Previous stroke (%)	2 (13)	3 (18)
Previous transient ischaemic attack (%)	2 (13)	2 (12)
Diabetes mellitus (%)	3 (19)	4 (24)
Prior hypertension (%)	5 (31)	6 (35)
Atrial fibrillation (%)	3 (19)	4 (24)
Baseline severity		
Scandinavian stroke scale *	37 (14)	34 (12)
Motricity Index *	39 (38)	37 (37)
Baseline haemodynamics		
Systolic blood pressure (mmHg) *	128.8 (17.6)	130.3 (18.3)
Diastolic blood pressure (mmHg)	75.6 (9.4)	76.4 (14.0)
Heart rate (bpm)	75.0 (10.1)	70.0 (15.4)

BPM: beats per minute. * Minimisation variables

TABLE 2

Functional outcome by treatment group. Frequency (%), mean (standard deviation), or median (interquartile range); comparison by student T test,* ANCOVA with adjustment for baseline, Mann-Whitney U Test,[†] or Chi square test[‡]

	Placebo (n=16)	D-amphetamine (n= 17)	2P
Day 35			
Fugl-Meyer score ^{§*}	33.5 (28.2)	35.9 (26.4)	0.81
Motricity Index [§]	46.1 (37.9)	47.5 (36)	0.26
Scandinavian Stroke Scale	40.2 (12.5)	39.1 (14.3)	0.33
Barthel Index	11.5 (7.3)	12.5 (5.8)	0.57
Modified Rankin Scale	3.2 (1.5)	3.5 (0.9)	0.59
Extended ADL *	18.1 (21.4)	14.6 (14.1)	0.58
Day 90			
Fugl-Meyer score *	35.2 (27.8)	37.6 (27.6)	0.81
Motricity Index	35.3 (40.9)	51.2 (36.8)	0.74
Scandinavian Stroke Scale	41.1 (13.8)	42.9 (11.8)	0.42
Barthel Index	12.9 (7.4)	14.3 (7.3)	0.20
Modified Rankin Scale	2.9 (1.4)	3.2 (1.0)	0.46
Extended ADL *	25.3 (25.2)	22.3 (19.9)	0.71
Discharge disposition (%)[‡]			
Institution	4 (25%)	2 (11.8%)	0.49
Home	8 (50%)	12 (70.6%)	
Length of stay (days) [†]	67 (39-93)	63 (48-92)	0.75

ADL: Activities of Daily Living

[§] Upper extremity

TABLE 3

Haemodynamic and cerebral blood flow measures 90 minutes following first (5mg, day 0) and second (10mg, day 4) doses of dexamphetamine. Mean (standard deviation), 95% confidence intervals (CI); comparison by ANCOVA with adjustment for baseline.

	Control 90 mins post	Dexamphetamine 90 mins post	Difference	95% CI	p
Day 0					
Peripheral					
Systolic blood pressure	124.4 (16.2)	136.8 (21.1)	11.2	1.1, 21.4	0.03
Diastolic blood pressure	72.9 (7.4)	79.0 (16.2)	5.8	-3.0, 14.5	0.19
Pulse pressure (mmHg)	51.5 (18.7)	57.8 (16.0)	6.0	-6, 18.3	0.33
Central					
Systolic blood pressure	110.9 (12.6)	122.0 (19.6)	9.5	0.64, 18.3	0.04
Diastolic blood pressure	73.7 (7.3)	80.0 (16.1)	6.1	-2.5, 14.7	0.16
Heart rate (bpm)	73.3 (11.4)	75.4 (17.1)	7.0	1.8, 12.6	0.02
Rate-pressure product	9047 (1503)	10322 (2879)	1579	453, 2705	0.08
Buckberg Index	168.9 (34.8)	170.9 (52.1)	-12.8	-33.0, 7.3	0.20
Augmentation index	130.1 (17.2)	130.7 (24.9)	-2.7	-13.7, 8.3	0.62
Ipsilateral-MCA velocity	25.6 (11.8)	29.4 (12.3)	-2.3	-9.8, 5.3	0.51
Contralateral-MCA velocity	29.7 (18.0)	30.9 (11.9)	1.3	-13.8, 16.2	0.84
Cerebral perfusion pressure	27.2 (12.4)	40.5 (16.2)	10.5	-4.98, 25.9	0.17
Day 4					
Peripheral					
Systolic blood pressure	127.3 (25.2)	131.7 (19.2)	7.0	-3.7, 17.7	0.19
Diastolic blood pressure	75.1 (17.0)	77.2 (12.6)	6.8	-2.0, 16.4	0.16
Pulse pressure (mmHg)	52.2 (20.4)	54.5 (17.5)	0.3	-9.2, 9.8	0.95
Central					
Systolic blood pressure	115.4 (21.7)	118.6 (18.6)	6.6	-3.6, 16.7	0.20
Diastolic blood pressure	75.7 (17.1)	78.0 (12.7)	7.2	-2.3, 16.8	0.13
Heart rate (bpm)	71.2 (10.7)	77.7 (22.6)	9.0	2.1, 15.9	0.01
Rate-pressure product	9111 (2402)	10106 (2794)	1620	419, 2822	0.01
Buckberg Index	166.1 (27.5)	167.4 (59.0)	-19.4	-41.6, 2.9	0.09
Augmentation index	139.8 (22.1)	134.8 (23.4)	-2.2	-18.2, 13.7	0.78
Ipsilateral-MCA velocity	25.8 (10.5)	28.5 (12.4)	3.3	-7.6, 14.2	0.40
Contralateral-MCA velocity	37.1 (11.1)	33.3 (19.6)	-0.4	-18.9, 18.2	0.97
Cerebral perfusion pressure	27.2 (9.7)	33.8 (17.5)	3.1	-11.0, 17.2	0.64
MCA middle cerebral artery velocity					

TABLE 4

Number of patients suffering serious adverse events (SAE) by treatment group. Frequency (%); comparison by Fisher's Exact test.

Event	Placebo	D-amphetamine
Recurrent stroke	1	0
Transient ischaemic attack	1	0
Pneumonia	0	1
Depression	1	1
Venous thromboembolism	0	1
Fall/fractured wrist	1	0
Total patients suffering a SAE	4	3


Figure Legends:

Figure 1: Trial Design

Figure 2a: Meta-analysis of amphetamine on motor impairment: Updated forest plot (meta-analysis) of effect of amphetamine on improvement in motor score

Figure 2b: Meta-analysis of amphetamine on blood pressure: Updated forest plot (meta-analysis) of effect of amphetamine on systolic blood pressure

Figure 1



*One placebo group patient did not receive final dose after an episode of agitation following the penultimate dose

Figure 2a

Review: Amphetamine for stroke recovery
 Comparison: 01 Recovery
 Outcome: 07 Improvement in motor score




Figure 2b

Review: Amphetamine for stroke recovery
 Comparison: 01 Recovery
 Outcome: 13 Systolic blood pressure

